For these reasons, in recent years new different therapeutic approaches were proposed to increase ALL survival outcome, such as molecular target therapy with the use of tyrosine kinase inhibitors [37], BCL-2 inhibitors [38], and proteasome inhibitors [39], or immunotherapy, in particular CAR T cells, antibody-drug conjugates and bispecific antibodies [40]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.